Locations:
Search
Study shows high rate of hematologic responses, low rate of disease progression
Bispecific antibody bridging therapy deepens durability of BCMA CAR T-cell therapy without overlapping toxicities in patients with relapsed/refractory multiple myeloma
Phase 2 study brings pivotal advances in treatment efficacy and safety for the most challenging-to-treat population
Advances in genomics, spinal fluid analysis, wearable-based patient monitoring and more
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Patient with quadruple refractory multiple myeloma achieves complete response with cell therapy
Distinct baseline immune profiles can predict response and resistance to different types of CAR-T cells.
Integrated care model reduces length of stay, improves outpatient pain management
Case study of radial-to-axillary nerve transfer for tumor-related deltoid nerve injury
National Blood Clot Alliance collaborates with faith-based organizations on first-of-its-kind church bus tour
AI-driven tools can streamline enrollment and improve efficiency across clinical trials.
Advertisement
Advertisement